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ABSTRACT
Nucleic acids have been found to prevent aggregation as chaperones, as well as act
as co-factors and promote aggregation of amyloidogenic proteins leading to various
diseases. Immunoglobulin G, IgG, are prone to aggregate as therapeutic proteins, and light
chains of IgG can form amyloid fibrils, causing a disease known as light chain amyloidosis.
Here we discuss the effect nucleic acids have on full-length immunoglobulin G
aggregation. Our results show G-quadruplex DNA, and bulk DNA lead to oligomerization
of full-length IgG, and induce increases in secondary structure. Tryptophan fluorescence
indicates structural changes are occurring in the presence of DNA. Additionally, IgG
oligomers promoted by G-quadruplex DNA are ThT positive. The increase in ThT
fluorescence suggests IgG oligomers induced by G-quadruplex DNA are in states similar
to amyloid intermediates. To our knowledge, interactions between nucleic acids as
potential co-factors and amyloidogenic light chain IgG have not previously been reported.
This research reveals interactions between DNA and IgG can occur, leading to the question,
do nucleic acids influence amyloid formation of light chain IgG?
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CHAPTER 1 ANTIBODIES

1.1 Overview of Immunoglobulin G and Structure
Immunoglobulin G (IgG) is a 150 kDa antibody protein. IgG is one of five classes
of immunoglobulins and has subclasses of its own 1. The primary role of IgG is to recognize
foreign invaders in the body and to initiate an immune response 2,3. It is composed of two
heterodimers 4, containing two heavy and light chains connected via disulfide bonds from
cysteine residues forming a “Y” shape 5, 6, Fig. 1.1. IgG is primarily composed of secondary
β-pleated sheet structures 1,5.
IgG subclasses 1-4 are approximately ninety-percent identical regarding amino acid
composition; however, small differences between the subclasses of IgG include length of
chains and differing sites of the disulfide linkages 1. These variations are iso- and allotypes
7

. Differences in amino acid sequence enable each subclass to interact with a distinctive set

of antigens 7. This is important as the primary function of an antibody is to recognize
different antigens and initiate proper pathways in response 1,3.
Heavy and light chains contain four and two domains, respectively, Fig. 1.1. This
allows them to have multiple functions and high specificity for several targets. The heavy
chain consists of a variable domain, VH and three constant domains, CH1, CH2, and CH3
1

1,7

. The light chain consists of a variable domain, VL and constant domain CL 1.

The stem of the “Y” shape 5,6 is formed through non-covalent interactions between the CH3
domains, as well as disulfide linkages in the hinge region. This is known as the Fc region
or the constant region 1,7.

Figure 1.1: “Y” structure of IgG represents light chain subunits (green) and heavy chain subunits (blue).
Disulfide bridges connect light and heavy chains (red), as well as noncovalent interactions.

Main differences in the constant regions among distinct subclasses of IgG are in
the hinge and CH2 domain, as this is the area of the Fc region that interacts with receptors.
Hinge regions also vary in length, which affect flexibility of the molecule 7.
The light chain and heavy chains forming the top of the “Y” are covalently linked
via disulfide bonds to form a region known as the Fab or the antigen binding site

1,8

. Each

variable domain consists of approximately three hypervariable loops, with large variance
2

in amino acid sequence

2,9

. The heavy and light chain β-sheet structures fold so the

hypervariable loops are in proximity, creating the antigen-binding site and the
complementarity-determining region, CDR

2,10

. This portion of IgG recognizes antigens

and indicates what antigens the antibody will target 2.
1.2 Immune Function
Antibodies recognize invaders in the body and initiate immune response. IgG
immune response can be broken down into two different categories: antigen binding and
initiating a proper response to the bound antigen 2. Immune response differs in individuals
as there are different alleles for IgG molecules, known as allotypes 7. This leads to variation
in amino acid sequence per individual, thus different immune responses.
Initiation begins with an interaction between the Fab and an antigen, which can
result in an immune response or activation of the complement system. The complement
system are proteins associated with plasma and membranes whose functions promote
pathogen defense and tissue homeostasis 11. The epitope is the binding site on the antigen,
which interacts with the paratope binding site in the CDRs of IgG 2. Antigen binding and
affinity are determined by hydrophobic and electrostatic interactions between the epitope
and paratope, in addition to shape complementarity 11, 12, Fig. 1.2.

3

Figure 1.2: Simplified depiction of antigen binding. Initiation begins as the antigen binds, due to shape
complementarity as seen above. The Fc region, or stem of IgG binds to receptors. This binding of the receptor
leads to initiation of the complement system or an immune response.

Adjustable binding in the CDR region allows for a wide variety of antigens and
ligands 5. Targets for IgG are dependent on the variation in amino acid composition in the
variable domains, as well as signaling induced by constant domains 5. While not fully
understood, allosteric effects upon antigen binding may induce structural alterations and
conformational changes in the Fc region, which may initiate effector functions 2,13.
The constant domains determine what effector functions an IgG will have 5. The
hinge region and CH2 domain primarily signal effector molecules or receptors. 1,7. These
interactions initiate defensive machinery in the immune system. Nearly all cells in the
immune system possess Fc receptors for antibodies and each facilitate different response
4

pathways 14. For example, the Fc region can interact with B and T-cells, and macrophages
11, 15

. These Fc receptor cells are highly specific and generally, receptors for one subclass

of IgG will not interact with other classes of immunoglobulin.
This response is important, as it triggers different pathways for actions such as
protein synthesis and cytotoxicity 16, Fig 1.2. CH domains contribute to the flexibility of
an antibody molecule, as well as the hinge region, which affects function 5,7. For instance,
IgG3 has a hinge region 62 amino acids in length, allowing for the flexibility between the
Fab arms and Fc. Flexibility of the molecule can determine antigen-binding affinity, as well
as receptor binding due to lack of exposure of the Fc receptor binding sites 7. Variable and
constant domains of IgG can interact with a wide array of molecules and cells. This concept
has made antibodies very useful in the pharmaceutical industry today.
1.3 Pharmaceutical Role of IgG
In the late 1980s Orthoclone, a monoclonal antibody product was introduced to the
market to inhibit organ transplant rejection in the body, initiating a branch of
pharmaceuticals that has emerged as a therapeutic giant in sales and number of products 17.
Various types and fragments of antibodies have been found to be useful in a wide range of
pharmaceutical products, due to their large array of targets in the body, and their ability to
elicit responses from several pathways

10

. They are also deemed safe to ingest

18

. IgG is

used to treat diseases and medical conditions such as rheumatoid arthritis, multiple
sclerosis, asthma, macular degeneration, and cancer

19

. Within ten years of being on the

market, Humira, medication for rheumatoid arthritis, contributed to over ten billion dollars
in sales globally 17. While antibodies are largely in demand, it can cost approximately $2.6
5

billion to develop and introduce a new pharmaceutical antibody and is a detrimental loss
when a product fails 18.
Engineered domain fragments of antibodies can be designed for specific therapeutic
needs 20,21. More specifically, the Fab region is separated from the Fc region and is used in
therapeutics to target diseases such as macular degeneration and Crohn’s disease

19,20

.A

little less than 50% of antibody fragment therapeutics contain the F ab region, making it
widely used 21. Unfortunately, without the Fc region present, this can lead to instability and
aggregate-prone antibody fragments 21.
Another type of therapeutic products are miniaturized antibodies, where engineers
remove domains not necessary for their therapeutic target and function 21. This small size
enables the product to enter areas a full-length antibody would not necessarily are able to
go

21

. This advantage allows them to reach tumors or tissue quicker than full length

antibodies 21. Miniaturized antibodies can also access locations such as enzyme active-site
pockets which are less accessible to full-length products 21.
Antibody-containing products have become even more useful as scientists
determined they cannot only be fragmented, but can also be conjugated with other
molecules, enabling delivery to new target sites, resulting in an increased range of
specificity in the body 21,22. For example, Mylotarg, Gemtuzumab Ozogamicin, is an IgG4
antibody therapeutic, used for leukemia chemotherapy and is conjugated with
calicheamicin

1,22

. Calicheamicin is known to bind to DNA, causing the double-stranded

structure to break, which then leads to apoptosis
conjugations to antibody pharmaceuticals.
6

23

. This is one example of many

Unfortunately, it is common for therapeutic proteins to become unstable leading to
aggregate formation, discussed in more detail in Section 2.2 1,24. It is of utmost importance
to find ways to prevent aggregation because these aggregates have been found to shorten
shelf life of products and in some cases, cause immunogenicity in patients

1,25

Additionally, these issues result in huge losses in revenue for pharmaceutical companies.

7

.

CHAPTER 2 AGGREGATION

2.1 Aggregation of Proteins
Protein aggregation is a common problem in the biological realm and in the
pharmaceutical industry

. This topic is widely studied; however, each protein’s

1,24,25

potential to aggregate varies depending on its physiochemical properties 25. While specific
interactions are different, stages in the aggregation pathway can be predicted, Fig. 2.1.

Figure 2.1: Simplified states of protein misfolding and aggregation. Aggregation can result in amorphous
aggregates that are disordered/globular, or oligomers and highly ordered amyloid fibrils. This can happen via
misfolded proteins, unfolding, or intermediate interactions. It is important to note, the folding pathway is
much more complex than this depiction.

8

When folded properly, for most proteins, hydrophobic regions tend to be buried
within the protein, with very little exposure, unless necessary for function. Misfolding and
unfolding of a protein lead to exposure of hydrophobic regions, which have the potential
to improperly interact with other peptides 1,26,27. These interactions have the potential to
cause intermolecular or intramolecular aggregation

27

. Native folding of a monomer is a

result of proper intermolecular interactions, while incorrect inter- and intramolecular
interactions lead to aggregate formation 28.
Folding and aggregation scenarios both rely on intermediates, whether those be
partially folded or denatured 27. Proper folding and aggregation are in competition with one
another and are dependent on physiochemical properties 29, such as increase in secondary
28

structures, or amounts of hydrophobic residues

. The folding and aggregation energy

landscape can be quite complex including interactions between the different states of
protein folding 29. For example, ordered aggregates can lead to native folding, intermediate
stages of folding, or amyloid fibril formation

29

. As a result of misfolding, or improper

interactions, amorphous aggregates can form. These are non-ordered aggregates, generally
formed through noncovalent interactions or incorrect disulfide bond formation.
Oligomerization and amyloid fibril formation are another possibility on the aggregation
pathway 27,30. Oligomers are said to be the building blocks of the highly ordered cross βsheet amyloid fibrils 28,31–33. Pathology of amyloid fibrils are described in Chapter 3.

9

2.2 Aggregation of Pharmaceutical Proteins
While proteins have been found to have high therapeutic value, it has also been
discovered that during pharmaceutical processes they have a propensity to aggregate 1,24,25.
This is an ongoing problem in the pharmaceutical industry, resulting in inadequate product
1,19,34

. Instability can be induced via production processes such as freeze-thawing, agitation,

and/or heat stress 25,35. Aggregation of as little as 1% of the total protein can greatly affect
the quality of the therapeutic, leading to issues such as loss of function and immunogenicity
34

. External factors including temperature, pH, protein concentrations, and production

processes can stabilize intermediates, or destabilize properly folded proteins 1.
In order to prevent the smallest amounts of aggregation, the FDA requires multiple
physiochemical and functional assays to be performed on each potential product

36

.

Product-related impurities must also be identified for the therapeutic to be considered for
approval, which includes small amounts of aggregates

36

. Immunogenicity assessment

protocols must also be followed to mitigate any issues with potential immune responses in
individuals 36. The FDA also requires any changes to pharmaceutical product development
(i.e., manufacturing, storage, shipping etc.) be reported or the drug will not be accepted.
Freeze-thawing and drying have previously been found to induce structural changes
in pharmaceutical proteins

1,25,37

. Freeze-drying of bovine IgG led to increasing amounts

of insoluble aggregates 1,38. Other research displayed incorrect disulfide bond formation as
a result of thermal stress 25.

10

Formulation types vary and can have negative effects during production and/or
delivery of the therapeutic. Liquid formulations, while relatively cheaper, are subject to
fragmentation, where portions of the peptide chain are no longer connected. This
destabilization can lead to further aggregation 37. Fragmentation of antibody therapeutics
is common 39,40. A direct result of fragmentation is the separation of the Fab from the Fc at
the hinge region 40. Research has shown when this separation occurs, the Fab is at risk for
aggregation due to instability

39

. This is a common issue that needs to be tested and

addressed while formulating biopharmaceutics as it will potentially become vulnerable to
degradation in the body with limited efficacy 37.
Lyophilization of the protein can also be problematic if not done correctly

37

.

Studies have shown incorrect moisture content leads to more aggregation. Around 1 to 8%
moisture when lyophilized is ideal, and more than that leads to negative effects

41

.

Rehydration of lyophilized antibody formulations may result in conformational changes 37.
If done too quickly, the antibody does not have sufficient time to return to its native state
of folding 37,41.
Agitation or shaking stress can occur during processes such as production or
shipping

42

. An air-water interface, an area in the container with air can interact with a

protein during formulation

43,44

. As a result, structural changes occur and hydrophobic

regions are exposed, when they would normally be buried within the structure of the
antibody 43. Exposure of hydrophobic regions from multiple protein monomers can lead to
inaccurate noncovalent interactions and aggregates 42. Insoluble aggregation occurs more
frequently in the presence of an air-water interface than without one 43.
11

An important characteristic of a biopharmaceutical is its inability to provoke an
immune response in humans 43,45,46. If a product leads to an immune response, this is called
immunogenicity, which can end the development of the therapeutic product

45

. This

immune response can result in anaphylaxis, or an attack on the product, essentially ending
its medicinal properties

45,47

. If therapeutic protein aggregation, or modification occurs

during the production process, the structure of the protein has been compromised

45,47

.

These changes can lead to new epitopes, or binding sites available to an existing antibody,
which can stimulate an immune response, causing immunogenicity

45

. Previously it has

been found that viruses and bacteria contain repetitively ordered epitopes and over time the
immune system evolved to attack these ordered antigens 45,46. Aggregated proteins display
similar properties of repeat epitopes, thus potentially resulting in a negative immune
response 45,46.
Therapeutic protein aggregation not only leads to loss in revenue, but a shortened
shelf-life for the biopharmaceutical products 1. More importantly, aggregates and
modifications can lead to immunogenicity

45

, therefore, developing methods to prevent

aggregation of therapeutic proteins is of utmost importance.

12

CHAPTER 3 AMYLOIDS

3.1 Amyloid fibrils in disease
Amyloid fibrils are at the forefront of biochemistry research due to their association
with a wide variety of diseases known as amyloidoses. It has previously been determined
amyloid fibrils are functional in bacteria and fungi, and recently in humans they are
predicted to isolate toxic intermediates of melanin synthesis and store hormones

48,49

.

Unfortunately, in humans, amyloids are well known to lead to pathological consequences
50

. Soluble oligomers intermediates are known to be the building blocks of insoluble

amyloid fibrils, which are then deposited into various organs depending on the type of
disease 28,31,33,51. Oligomers are also considered toxic if they are on the fibrillar pathway of
aggregation 53. They are classified as highly ordered structures composed of cross β-sheets
forming ribbon-like arrangements 50. These cross β-sheet structures are different to each
disease, and within a specific disease as well 54. Hydrogen bonding between β-sheets forms
an intermolecular network 55. Their role in local and systemic amyloid diseases have been
studied over the last few decades.
Prior knowledge of amyloid fibril diseases can be insightful for less known
amyloidoses and can be used to predict aspects such as formation and pathways.
Pathologically, Alzheimer’s disease (AD) is one the most studied neurodegenerative
13

diseases. Two proteins are the main contributors to AD; tau is known to form
amyloid fibrils and neurofibrillary tangles 31. β-amyloid 42 is the other precursor protein
for Alzheimer’s disease; its aggregation can result in mature amyloid plaques formed by
fibrils. Both of which are deposited into the brain 31,52,56. This causes large amounts of cell
death and memory loss

. Parkinson’s disease is another neurodegenerative disorder in

56

which amyloid fibrils are formed, caused by the aggregation of α-synuclein 57. α-synuclein
fibrils develop into Lewy bodies, characteristic of Parkinson’s disease 58. Neurons become
dysfunctional due to these aggregates

59

. Protofibrils are formed from oligomeric α-

synuclein, which gradually transform into insoluble fibrils 57,59.
PrP is associated with degenerative diseases and is defined by conformational
changes to increased β-sheet structure and amyloid fibril formation from the original αhelical protein

60

. Prion disease is also known as transmissible spongiform

encephalopathies or TSE

61

. This conformational change leads prion protein down a

pathogenic pathway, and results in a protease-resistant protein

61

. Generally

neurodegenerative diseases are widely studied, but amyloid aggregation can affect multiple
areas of the body as well.
While fibrils are toxic to cells, oligomeric species, or pathogenic oligomers have
been deemed toxic as well

31,33

. Two different Aβ oligomers of similar size were studied

for their role in cellular toxicity 62. While they were relatively the same size, the more toxic
oligomer was soluble and contained two hydrophobic regions exposed to solvent 62. It is
believed this exposure allows them to permeate cell membranes

14

62,63

. Additionally, they

maintained some β-sheet structure. Less toxic oligomers were insoluble and were not
composed of β-sheets 62.
Light chain amyloidosis is the most common form of systemic amyloidosis,
meaning it can affect multiple organs. The light chain from immunoglobulin G can form
fibrils when stressed. This is described in more detail in section 3.3.
3.2 Formation and Structure of Amyloid Fibrils
While specific details of amyloid formation are still unknown and vary with the
protein they are composed of, a general pathway is known and used to mimic formation in
vitro

57

. Amyloid formation occurs within three phases

57,64

. Initiation is considered the

rate-limiting step or the lag phase and is dependent on the formation of oligomeric species.
This process is known as primary nucleation 64. Once this initial interaction happens, the
core of the amyloid fibril has been established and other proteins or peptides join the
oligomer

27

. The lag phase is complete once intermediate soluble oligomers are formed.

Oligomers then associate to form protofibrils which is a quick process known as the growth
or elongation phase 57,64–66.
In addition to the rapid growth, the presence of fibrils has been found to increase
the rate of further fibril growth. The hypothesis is that after mature fibrils are formed, the
surfaces speed nucleation processes of new aggregates
positive feedback, or secondary nucleation

64,65

67

. This process is known as

and it is dependent on the number of

monomeric and oligomeric species, and fibrils present. Once secondary nucleation begins,
it is generally known to be the primary mode of fibril elongation 68. The saturation phase
15

can be defined as a steady state, where little changes are seen over time and monomeric
species are in equilibrium 68.
A natively folded protein or denatured protein can evolve into a partially
folded/misfolded intermediates

57,68

, which may interact with other proteins in similar

states 27. It is important to note fibril morphology has been found to be dependent on the
protein, including the conditions in which the fibrils are formed 54.
3.3 Light Chain (AL) Amyloidosis
Although it is less known, light chain amyloidosis is the most common form of
systemic amyloidosis 69–71. Systemic amyloidosis occurs when multiple organs are affected
by protein aggregates, as opposed to local, where only one organ is involved

69

.

Immunoglobulin light chains are produced in bone marrow and plasma cells. Light chain
(AL) amyloidosis is a bone marrow disorder which occurs when plasma cells secrete
increasingly high amounts of kinetically unstable light chain dimers which are held
together via a disulfide bond 69. Monomeric light chain consists of one VL and CL domain.
The overproduction of light chain fragments, particularly the VL domain, misfold and bind
together to form fibrils 72.
More specifically, VL domains adopt highly rich beta sheet secondary structures 71.
Full length light chains have been found in amyloid aggregates but most often fibrils are
composed of fragments of light chain, the VL domain with as many as 60 amino acid
residues from the constant domain, CL 72,73. AL amyloids are insoluble and are composed
of cross-β sheet structures 74. As a result, these fibrils are deposited in the heart and kidneys;
16

however, other organs such as the stomach, intestines, and skin can be affected as well
9,51,71,75

. The light chains are delivered to different parts of the body via the blood stream 9.
Variable domains have been found to be thermodynamically unstable, thus more

prone to form aggregates, including fibrils

51,76

. To determine why some light chains are

more susceptible to aggregation, researchers have investigated thermodynamic and kinetic
stability of light chains. In this case, kinetic stability represents the free energy between
transition states and native states of folding

76

. If a protein is kinetically unstable, it will

unfold faster. This study determined light chain dimers from AL amyloidosis patients are
kinetically unstable and unfold quicker. This makes them vulnerable to proteolysis or the
break-down of peptide bonds 76. Light chains that are not produced in a patient with AL
amyloidosis did not unfold quickly and were more kinetically stable, suggesting the
limiting factor in AL amyloid formation is the unfolding of the protein 76.
While true for most amyloid formations, AL-amyloidosis is known to be
polymorphic, where conformational differences in mature fibrils are seen. Cryo-EM
images of fibrils have been obtained in various studies and can be used for fibril analysis
77

. As mentioned above, oligomeric intermediates are a large part of fibril formation.

Oligomeric species can vary within different types of light chain and light chain fragments
involved in amyloid formation 78.
Structural differences in amyloid fibrils are seen in biological systems and in vitro.
This can be attributed to the environment and experimental conditions in which the fibrils
are formed. Previous research has shown a “conserved building block” forms various
protofibril structures 55. Variation in fibril structures makes it difficult to target amyloid
17

diseases, even though the building blocks are similar, which can be seen using cryo-EM
images of cross sections of fibrils 55. For example, the dimensions of the fibrils can differ.
Cryo-EM can determine the width of amyloid fibrils formed by IgG light chains and
previous studies have shown widths ranging from 8 to 22 nm, with different assemblies 55.
Amyloid fibrils are represented by increased secondary structure, β-sheets, and low
energy aggregates, as they are highly ordered

29

. There is currently no cure for AL

amyloidosis; however, understanding the building blocks and pathology are most
important for determining where to begin when formulating a cure

55

. We can use our

knowledge of different amyloid diseases to predict pathology and hypothesize whether
different biomolecules influence formation of detrimental fibrils.

18

CHAPTER 4 COFACTORS AND MOLECULAR INTERACTIONS WITH PROTEINS

4.1 Co-factors
While investigating amyloid formation, it is important to determine which
molecules increase or decrease aggregation. Co-factors are accessory molecules present in
amyloid deposits and have been found to promote fibril formation and increase the amount
of oligomeric species present 51,55,69,71. On the other end, chaperones are molecules which
aid in proper folding of proteins, or they can prevent aggregation

27,30,79,80

. The effect a

specific molecule has on aggregation is dependent on the protein of interest, and in some
cases, varies with mutations to the protein as well 51.
Previously, amyloid deposits from neurodegenerative diseases were characterized,
and determined to contain non-fibrillar components, and components of extracellular
matrix

70,81

. This included unbranched, negatively charged glycosaminoglycan (GAG)

molecules like heparin

66

. Heparin is an extracellular component found to elevate fibril

formation of proteins such as tau and α-synuclein 82. Tau isoforms contain repeat regions
that carry positive charge

52,83

negatively charged co-factors

. Propagation of tau has been found to be assisted by
52

. Additional examples of GAGs and extracellular

components are dermatan sulfate, chondroitin sulfate A, and keratan sulfate

51,70

Polyphosphate, polyP, is another negatively charged molecule found in tissues in a range
19

.

of concentrations

84

formation in vitro

84

. Research determined it to be a cofactor that accelerates fibril
. Another protein affected by co-factors is the prion protein (PrP).

While it is known to self-propagate, co-factors such as GAGs and lipids have also been
found to increase propagation of PrP in addition to increase infectivity 85.
Light chain fibrils have also been found to be associated with different co-factors
in extracellular deposits 51,70,74,86. SDS-PAGE experiments displayed interactions between
light chain fibrils and GAGs 70. Other work suggested fibril formation was promoted in the
presence of some extracellular components 70. One study investigated the effect of different
GAGs on light chain amyloid formation and determined they had different effects of
formation. Heparan sulfate accelerated fibril formation in different mutants of light chain,
where it did not promote any formation in others 86. It is evident some negatively charged
molecules can promote fibril formation in vitro and it is no surprise nucleic acids, with
their negative backbone, have been found to not only promote oligomer formation 30,79 but
also interact with soluble oligomers which form amyloid fibrils 66,87.

4.2 Nucleic Acid interaction with amyloid-forming proteins
Characterization of amyloid plaques is important to fully understand the pathology
of different amyloid diseases. Throughout the years, composition of amyloid plaques has
uncovered they are not solely composed of their primary protein

88

. Specific plaque-

associated proteins and peptides have been found in amyloid deposits. For example, work
by Schmidt showed the presence of phosphotyrosine-containing proteins 89. Ginsberg used
20

acridine orange to determine whether plaques and neurofibrillary tangles from cranial
tissues of AD patients were embedded with RNA 88. The extracellular deposits fluoresced
in orange, suggesting RNA was associating or interacting with amyloidogenic proteins 88.
Transmission electron microscopy (TEM) images have shown nucleic acids of RNA and
DNA are embedded in Aβ plaques as well as GAGs and metal ions 81.
Since this research was published in 1997, various studies have shown not only are
nucleic acids embedded in amyloid plaques, but they also been found to interact with fibril
forming proteins

87

, including promoting amyloid formation in different diseases. More

importantly, oligonucleotides, as short as 33 nucleobases long, were found to accelerate
fibril formation of a short peptide chain 87. Previously, DNA was found to interact with Aβ
1-42; however, no correlation was found between fibril formation and this contact 90. While
no correlation was seen, the interaction is significant because nucleic acids have been seen
in amyloid plaques 81,88,90.
As mentioned above, tau is another protein associated with AD. Previous work
displayed tau isoforms and constructs were influenced by RNA, where multiple RNA
species reduced assembly times significantly of a tau construct, K19 83. Truncated forms
of tau were also studied; when heparin and RNA were introduced, fibril formation was
observed

91

. Heparinase and RNase are known to digest these co-factors, and once

introduced to the samples, a decrease in ThT fluorescence was seen, suggesting less fibril
formation occurred 91.
Additional studies were performed to investigate the role RNA has on the growth
of tau fibrils 52. In the presence of polyA RNA, tau constructs K18 and K19 fibril formation
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was observed. The absence of RNA in tau fibril seeds resulted in an abrupt halt of
“template-assisted” fibril formation, thus the monomers present were not elongating tau
fibril seeds any longer 52.
In addition to GAGs and lipids, nucleic acids are also associated with PrP
propagation 60,61. As a reminder, PrP is converted to a protease-resistant state, PrPSc. When
RNAse was introduced into samples containing PrPSc, its amplification was eliminated.
After the addition of mammalian RNA, amplification resumed 61. It has also been proposed
that nucleic acids catalyze the conversion of PrP to PrPSc 92. Small dsDNA have high
binding affinity to PrP, and research has shown it catalyzes the conformational change to
the soluble, β-sheet conformation, PrPSc 92. As mentioned, PrP is known to self-propagate.
A spontaneous conversion from PrP to the protease-resistant state occurs and as a result,
PrPSc catalyzes additional conformational changes, known as positive feedback. As nucleic
acids catalyze such conformational changes, PrPSc is generated, thus activating this positive
feedback pathway 92.
To our knowledge, there is no previous research on the effects nucleic acids have
on IgG, including light chain IgG. Generally, amyloidogenic proteins follow similar
pathological pathways. We know fibril formation of light chain IgG can be promoted by
heparan sulfate thus it is possible nucleic acids have the potential to interact with IgG light
chains as well.
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4.3 Nucleic Acids and their role as chaperones
Chaperones aid a protein in achieving its native conformation at various points in
the folding pathway. Generally, most proteins need assistance, and chaperones can support
folding or provide necessary environments for the proper folding 27. Chaperones known to
prevent protein aggregation are called holdases 80,92.
Previously the role nucleic acids play in protein aggregation has been investigated.
A variety of different RNA and DNA sequences were tested to determine their efficacy
with preventing citrate synthase aggregation 80. It was determined nucleic acids are highly
efficient chaperones, more productive than other known molecular chaperones, such as
GroEL 79.
Additional work showed chaperone activity varied between a large group of
random sequences, suggesting there was a particular sequence or motif which encoded for
better chaperone activity

80

. Bioinformatics determined sequences containing poly-G

motifs that are known to form G-quadruplex structures showed significant holdase activity
80

. G-quadruplex structures are tetrads of guanine bases, stabilized by π-stacking and salts

80

. The guanine bases interact via Hoogsteen hydrogen bonding. G-quadruplex can have

parallel, anti-parallel or mixed orientation regarding direction of the ssDNA strand.
Sequence 576 or Seq576 is a guanine-rich ssDNA with a relatively high melting point 80.
It is 20 nucleobases long with the sequence, 5’ TGT CGG GCG GGG AGG GGG GG
3’. It was determined to form parallel G-quadruplex structures and is known to interact
with different proteins, efficiently preventing aggregation of citrate synthase 80.
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Nucleic acids have also been found to promote oligomerization of various proteins
30

. This research focused primarily on luciferase and MDH protein aggregation in the

presence of nucleic acids. Thermal and chemical denaturation assays were performed with
and without nucleic acids. The addition of nucleic acids prevented the proteins from
becoming insoluble, inhibiting their aggregation. TEM images display oligomerization
when DNA is present 30.
In addition to oligomerization, CD spectra performed in this study showed changes
in secondary structure in the presence of DNA 30. Secondary structure was lower than that
of the native state. Light scattering data displayed oligomerization of luciferase promoted
by nucleic acids occurred faster than luciferase aggregation when DNA was not present 30.
Nucleic acids have been found to act as co-factors and promote amyloid formation in a
wide variety of proteins, as well as prevent aggregation of different proteins by assisting
soluble oligomer formation

30,52,60,61,83,92

. In this study, we examined if nucleic acids

promote or prevent full length IgG aggregation, or if they have no effect at all. This
information may lead to future research of light-chain amyloidosis in the presence of DNA.
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CHAPTER 5 RESULTS

5.1 Thermal Aggregation
To begin, it is important to establish a thermal aggregation assay for IgG to test if
the addition of nucleic acids influences aggregation. Heat stress is known to destabilize
multiple proteins, leading to the formation of aggregates, or denatured protein. This assay
was developed from methods previously used in the laboratory to test nucleic acid sequence
dependence on chaperone activity

79

. I used circular dichroism to determine the melting

point of the IgG I used for my experiments, which was near 72°C, as this is the temperature
at which we would expect aggregation to begin. The experiment was performed with a
ThermoMixer at 72° C for 15 minutes and 400 rpm. I then spun down the sample to separate
soluble and insoluble proteins via centrifugation (4°C, 15 min, 16.1k x g in a microfuge)
with SDS-PAGE to monitor aggregation and solubility.
I first optimized the experiment to determine ideal concentrations of IgG (1.3μM)
and nucleic acid sequences. Then, I determined the lowest concentration of DNA that could
be used to prevent aggregation of IgG for maximum sensitivity. As an initial control, I
evaluated how the addition of bulk htDNA affected IgG aggregation.
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Figure 5.1: (A) Thermal aggregation assay of 1.3μM IgG +/- 6.5μM bp htDNA. To evaluate results, a spin
down assay was paired with SDS-PAGE. After heating to 75°C for 15 minutes, for IgG alone, most of the
protein can be seen in the insoluble (I) fraction. With the addition of htDNA, the protein can primarily be
observed in the soluble fraction (S). (B) Concentration dependence of Seq576, ratios are DNA:Protein. A is
a representation of triplicate experiments (Appendix, Fig. A.1A).

After thermal aggregation and spin down assays, I ran the samples using SDSPAGE and results indicated IgG without nucleic acids were found primarily in the insoluble
fraction, Fig 5.1 (A). I also tested significantly higher ratios of htDNA to determine
concentration dependence. At higher ratios, Fig 5.1 (B), htDNA is more effective at
preventing aggregation of IgG, but is still effective at a ratio of 5:1. The addition of htDNA
resulted in more protein remaining soluble. This data suggests htDNA is preventing IgG
from aggregating and becoming insoluble. After establishing a control with bulk htDNA,
we introduced G-quadruplex forming sequence, Seq576

80

. In the presence of Seq576,

nearly all IgG in the sample remained soluble, Fig 5.2 (A). This data shows Seq576 is more
efficient in preventing aggregation than htDNA. As a negative control, we tested20
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nucleotide long ssDNA Seq42, which has previously been determined to hold no chaperone
activity

80

. We tested this as it is the same length as Seq576 and does not form G—

quadruplex structures.

As expected, ssDNA, Seq42 had no effect on preventing

aggregation of IgG. We also tested how efficient Seq576 is as a chaperone by testing
different concentrations of Seq576, Fig 5.2 (B). It appears at significantly low ratios,
Seq576 is less effective at preventing aggregation of IgG, where values above 1:2 ratios
are more effective. Compared to htDNA, Seq576 is more efficient, as we need much less
amount of Seq576 to work well at preventing aggregation.

Figure 5.2: (A) Thermal aggregation assay of 1.3μM IgG +/- 0.65μM molecules Seq42 and Seq576. To
evaluate results, a spin down assay was paired with SDS-PAGE. After heating to 75°C for 15 minutes, for
IgG alone, most of the protein can be seen in the insoluble (I) fraction. With the addition of Seq576, almost
all the protein can be observed in the soluble fraction (S). (B) Concentration dependence of Seq576, ratios
are DNA:Protein. A is a representation of triplicate experiments (Appendix, Fig. A.1B).

It is clear the addition of DNA influences solubility of IgG after thermal stress, likely due
to nucleic acids interacting with IgG and preventing their aggregation. We next observed
how G-quadruplex Seq576 affected IgG aggregation due to agitation stress.
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5.2 Agitation Assay
Agitation, also known as shaking stress, is a known cause for protein aggregation,
including amorphous aggregation, oligomeric intermediates, and the formation of amyloid
fibrils 93,94. It is believed shearing can impact aggregate formation, but the presence of an
air-water interface can also induce aggregation 44. Previously, research was performed on
hen lysozyme to observe amyloid formation in vitro, and it was observed agitation stress
of 700 rpm induced amyloid formation 94. Agitation-induced aggregation of IgG was also
studied previously, as shearing conditions can denature antibodies. Agitation has been
found to disturb antibody function, and overall antigen-binding activity was reduced 1.
Shaking can also be used to investigate amyloid formation without additional heat stress
95

. I performed agitation assays to determine if the addition of nucleic acids influenced

agitation-induced IgG aggregation.
To observe aggregation, air-water interface has proven to be an important factor.
Previous research determined the absence of a headspace within a sample vial resulted in
very little agitation-induced aggregation 43, therefore, I used 1.5mL microcentrifuge tubes
for the experiments with a final volume of 300μL, chosen to allow for an air-water
interface, shaken at 1200 rpm (methods modified from Kiese et al. and Serno et al.

43,44

).

Samples were shaken for 72 hours at 60°C 44. The lower temperature was chosen to prevent
melting from being a factor in the experiments. The agitation assay was paired with a spin
down assay, (as mentioned in Thermal Aggregation) and SDS-PAGE.
After optimization, a final concentration of 0.5 mg/mL of protein was chosen, with
a stoichiometric ratio of 1:1 Seq576 to IgG. I tested IgG with and without the addition of
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Seq576. After shaking, the IgG alone sample indicated faint amounts of IgG in the
insoluble fraction (I) and aggregation was seen. With the addition of Seq576, the antibody
is no longer present in the insoluble fraction, resulting in a bolder band in the soluble
fraction (S), Fig. 5.3.

Figure 5.3: Agitation assay of 3.3μM IgG +/- 3.3μM molecules Seq576. To evaluate results, a spin down
assay was paired with SDS-PAGE. 1200 rpm shaking was performed for 72hrs at 60°C. IgG alone, a small
amount of protein is observed in the insoluble (I) fraction. With the addition of Seq576, almost all the protein
can be observed in the soluble fraction (S). This is a representation of triplicates (Appendix, Fig. A.2).

Nucleic acids are potentially interacting with IgG and assist in maintaining solubility
during agitation stress. The addition of nucleic acids is preventing aggregation of IgG;
however, it does not comment on whether the nucleic acids are changing the oligomeric
state of the protein. These results led us to inquire more about IgG-DNA interactions, using
a variety of techniques for structural analysis.
5.3 Non-reducing conditions
With the addition of nucleic acids, our previous results showed IgG remained
soluble after heat stress, Fig 5.1 and Fig 5.2. It was important to observe the protein after
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thermal aggregation and without a reducing agent 25 to gain more information about how
nucleic acids are affecting IgG during heat-stress. Dithiothreitol, DTT, is a reducing agent
that is used to reduce disulfide bonds. If a reducing agent is not present in the samples,
disulfide bonds will still be intact. If nucleic acids are binding IgG, as a monomer and
preventing any oligomerization, we would expect to see a strong band around 150 kDa in
the soluble fraction, as this is the monomeric molecular weight of IgG 1,25. If nucleic acids
are inducing formation of oligomeric IgG, we expect to see bands larger than 150 kDa in
the soluble fraction.

Figure 5.4: Thermal aggregation assay of 1.3μM IgG +/- 0.65μM molecules Seq576. Samples were observed
+/- DTT reducing agent. 1st column: IgG -DTT, without nucleic acids. 2nd column: IgG +DTT, without
nucleic acids. 3rd column: IgG -DTT, +Seq576. 4th column: IgG +DTT, +Seq576. Samples were heated to
75°C for 15 minutes. The IgG containing Seq576 and no DTT, did not travel in the gel, suggesting proper
monomeric species are not present (red box). Additionally, the band directly above 250 kDa in S 3 rd column
potentially represents the formation of dimers.
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Figure 5.5: Thermal aggregation assay of 1.3μM IgG +/- 6.5μM bp htDNA. Samples were observed +/- DTT
reducing agent. 1st column: IgG -DTT, without nucleic acids. 2nd column: IgG +DTT, without nucleic acids.
3rd column: IgG -DTT, +Seq576. 4th column: IgG +DTT, +Seq576. Samples were heated to 75 °C for 15
minutes. The IgG containing htDNA and no DTT, did not travel in the gel, suggesting proper monomeric
species are not present (red box).

Non-reducing conditions for IgG without nucleic acids (1st column) displayed
bands at the top that did not enter the gel (blue box Fig 5.4) in both the total and insoluble
fractions. This means assemblies had a high molecular weight (MW) and were too large to
travel in the gel. In the soluble fraction (1st column) for IgG without nucleic acids, we see
a band at approximately 250 kDa, and it is important to note we do not see an additional
band at the top of the gel that did not travel.
Non-reduced samples containing IgG and nucleic acids (3rd column) resulted in
bands present at the top of the gel, where the loading wells are located for all three fractions
(red box Fig 5.4), with different band intensities. In the soluble fraction we see a larger
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band intensity than in the insoluble, indicating most of the protein remained soluble.
Additionally, there is a band above 250kDa, which may represent the presence of dimers;
however, we cannot conclude molecular weight as there is no marker for that band. This
information shows that covalently linked soluble oligomers are formed when nucleic acids
are present. With the addition of htDNA, the same trends were seen, Fig 5.5. The main
difference in band patterns between htDNA and Seq576 samples was that Seq576
contained a band above 250 kDa that may represent dimers, where htDNA did not show a
band in that position (3rd column).
When comparing the insoluble fractions of IgG with and without nucleic acids (3rd
and 1st columns), the band patterns are different. We observe bands at the top of the gel in
both insoluble fractions, with varying intensities. This shows for both samples, assemblies
of IgG are forming that are too large to enter the gel. In the 1st column, the insoluble fraction
band is much more intense, indicating most of the protein is insoluble, compared to when
nucleic acids are present, where most of the protein remained soluble.
Comparing soluble fractions of both IgG with and without nucleic acids, (3 rd and
1st columns) we did not see monomeric IgG in either sample, at 150 kDa. Additionally, we
see bands in both columns; however, the patterns and intensities are different. The only
band present for IgG without nucleic acids (1st column) is near 250kDa, and is very faint
in intensity, suggesting only small amounts of protein remain soluble. In the 3 rd column,
similarly, we see a band at 250 kDa. Two additional bands are seen in the soluble fraction
with nucleic acids. A band that did not enter the gel, showing the formation of soluble
oligomers too large to enter the gel, and a band above 250kDa, Fig 5.4, suggesting the
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formation of dimers. This is telling us nucleic acids are affecting the assembly of soluble
IgG and leads to different formations of oligomers than samples without nucleic acids, and
additional structural studies are required to further investigate this concept. The main
difference between the addition of Seq576 and htDNA, is that there is no comparable band
above 250kDa in the presence of htDNA, Fig 5.5, suggesting it may not lead to the
formation of dimers.
Overall, we determined the addition of nucleic acids do not on their own
significantly assist with proper folding resulting in monomeric IgG. Instead, they assist in
the assembly of soluble oligomers that are covalently linked. Band patterns of soluble
fractions for IgG with and without nucleic acids, indicate DNA leads to a different
assembly pattern of the protein. These results are consistent with previous results from our
lab of nucleic acids promoting the formation of oligomers

30

. It is important to note that

some soluble oligomeric species are precursors for amyloid fibrils, including in AL
amyloidosis. We further evaluated this relationship between IgG and DNA using light
scattering assays.
5.4 Light Scattering Assay
Light scattering experiments can be used to observe the effect DNA has on IgG
aggregation in real time. This method has been used previously to observe protein
aggregates 96, in addition to monitor holdase activity of different ssDNA sequences 30,80,96,
as well as the activity of many protein chaperones, such as heat shock proteins 97. There is
a direct relationship between light scattering intensity and the number of aggregates or
relative sizes of species in solution. If light scattering intensity increases, this is indicative
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of aggregate formation in solution, or the presence of large assemblies 96,97. While heating
the samples and exciting at 340 nm, we recorded emission intensity at 340 nm over time.
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Figure 5.6: Light scattering assay of 1.3μM IgG with and without nucleic acids. The x-axis represents time, in addition to changes in temperature.
Time = 0 min is equivalent to 25°C pre-melt. Time = 42 min is after heating to 85°C, and time = 84 min represents cooling to 25°C. (A) IgG
without nucleic acids; a significant increase in light scattering was observed around 72.5 °C and fluctuated while cooling after the temperature
reached 85°C. (B) IgG with 0.65μM molecules Seq576; a slight increase in light scattering was observed around 72.5 °C and plateaued at 85ᵒC.
(C) IgG with 6.5μM bp htDNA; similar to Seq576 an increase in light scattering was observed around 72.5 °C and plateaued at 85°C, although
slightly larger than IgG + Seq576. This is a representation of duplicate experiments (Appendix, Fig. A.13, A.14, A.15).

When IgG was heated, a significant increase in light scattering was observed around
35 minutes, which occurred at approximately 72.5°C, Fig 5.6 (A). This was expected, as
we know IgG aggregates in the absence of nucleic acids. Upon cooling, fluctuations in light
scattering were observed, and a slight decrease occurred over time. Spin down assays
showed us IgG precipitates out of solution, and this could have been a result of the protein
falling to the bottom of the cuvette. This data confirms the results from thermal
aggregation, agitation, and spin down assays.
Upon heating IgG with the addition of G-quad Seq576, the sample displayed an
increase in light scattering intensity at approximately 35 minutes, at a similar time and
temperature as IgG without DNA, Fig 5.6 (B). Increases in the light scattering intensity
halted at approximately 85°C, at a much lower maximum intensity than when DNA was
not present. The light scattering intensity remained steady upon cooling. This information
confirms results from previous experiments, suggesting small oligomeric species of IgG
are forming in the presence of Seq576 and/or large aggregates are being prevented from
forming.
Similar results were seen with the addition of bulk htDNA, where light scattering
intensity increased in a similar manner, and upon cooling, remained steady, Fig 5.6 (C).
Due to differences in light scattering upon the addition of different types of DNA,
understanding secondary structure of IgG aggregates and smaller species present with
DNA is important.
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5.5 Transmission Electron Microscopy
Spin down and light scattering data combined suggest structural changes, and the
formation of oligomeric IgG in the presence of nucleic acids. Electron microscopy can
provide insight into relative size and structures of these oligomeric species. We also used
EM as a confirmatory technique to determine if previous data is the result of oligomeric
formation. Oligomerization can result in a wide variety of structures, and morphologies
between different proteins, and mutations of a protein. For example, a variety of single
point mutations all resulted in the formation of different oligomeric intermediates of ALamyloidosis 78. It is important to note, there is a difference between soluble oligomers and
oligomeric intermediates, where intermediate is suggesting a form of the protein in between
two different phases of a pathway. On-pathway oligomeric species are usually referred to
as spherical intermediates; however, other terms such as fuzzy balls and annular aggregates
have also been accepted 78.
Based on previous data, we expected to see miniscule amounts of IgG in the soluble
fraction when nucleic acids are not present, Fig 5.7, as most of the protein pelleted out
following thermal aggregation and spin down assays, Fig 5.1, Fig 5.2. This is true for other
proteins in the absence of DNA, such as MDH and luciferase, where thermal and chemical
denaturation led to large amounts of protein precipitating out of solution 30. As expected,
we see very little IgG present in TEM images of the soluble fraction, Fig 5.7.
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Figure 5.7: EM data for IgG without nucleic acids post thermal aggregation and spin down assays. Note,
these images represent the soluble fraction after the assays. As expected, very small amounts of IgG were
seen in the soluble fraction, with little to no oligomerization. Scale bars represent 100 nm.

When Seq576 is present in IgG samples before heating, previous data determined
most of the protein remained soluble after heating. This is similar to previous data obtained
in lab, where the presence of DNA prevented insoluble aggregation of various proteins,
and almost all of the protein remained soluble 30. We expected to see large amounts of IgG
present in TEM images of the soluble fraction when Seq576 is present. Thermal
aggregation and SDS-PAGE data, suggest oligomerization occurred, including structural
changes. As predicted, Fig 5.8, soluble oligomers of IgG are present in TEM images when
Seq576 was added. Additionally, images of IgG in the presence of htDNA were taken via
TEM, Fig 5.9. It does appear some soluble oligomers are present, with similarities and
differences to oligomers formed when Seq576 was present. As expected, we do see IgG
present in the soluble fraction, backing up previous data from thermal aggregation assays.
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Figure 5.8: EM images of 1.3μM IgG + 0.65μM molecules Seq576 post thermal aggregation and spin down
assays. Significant amounts of oligomers were seen. Note, these images represent the soluble fraction Scale
bar: 100 nm

Figure 5.9: EM images of 1.3μM IgG + 90μM bp htDNA post thermal aggregation and spin down assays.
Note, these images represent the soluble fraction. We see some oligomerization occurring; however,
somewhat differently from when Seq576 is introduced to IgG. Scale bar: 100 nm

Our research thus far indicates in the presence of DNA, soluble oligomer IgG
formation is occurring via prevention of aggregation. Light scattering results indicated the
amounts of species in solution are different and/or are relatively different in size than that
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of samples with no DNA. We can learn more about the secondary structure of these
oligomers using CD.
5.6 Circular Dichroism
We have thus far found that the addition of nucleic acids are preventing IgG from
becoming insoluble, and that the aggregates have disulfide linkages, but we have not yet
discerned more information about the structure of the oligomers. To further investigate
how DNA affects the secondary structure of IgG, I used circular dichroism (CD). Circular
dichroism is used to study structural properties of proteins 98. CD can be quantitated using
algorithmic software and through comparison to reference spectra it can give valuable
insight into the composition of secondary structures, as well as indicate when
conformational changes occur 99. Experimental data can be compared to different reference
spectra.
As previously discussed, if nucleic acids were acting as foldase chaperones 80 after
a full melt, we would expect to see spectra indicative of properly folded IgG and little
change in the spectra would be observed between the pre- and post-melt data, as foldases
assist in folding. We know monomeric IgG is not present after thermal aggregation,
therefore we expect the addition of nucleic acids will result in changes to secondary
structure of IgG. Holdase chaperones assist in preventing aggregation, and post-melt
spectra could be different than pre-melt spectra, and an increase or decrease of secondary
structure should be observed depending upon the structure of the protein while in the
oligomers. We expect to see changes in secondary structure, since we know DNA is
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preventing aggregation, and previous data shows nucleic acids can act as holdase
chaperones. Previous research showed the addition of nucleic acids resulted in low amounts
of secondary structure for oligomers than that of the native state for proteins, luciferase and
MDH 30,79,80.
I used CD to evaluate IgG with and without Seq576 to investigate what structural
effects nucleic acids contribute to IgG. Starting at room temperature, I heated the samples
slowly with a ramp rate of 1C/min to 85ᵒC. After, I performed a reverse melt, with the
same conditions, from 85ᵒC to 25ᵒC and periodically recorded measurements.
The structure of native IgG monomers, including the VL domain, are highly rich in
beta sheets

1,72

. Spectra for IgG with and without nucleic acids was measured at room

temperature pre-melting, Fig 5.10. The data suggests the main secondary structure for IgG
is β-sheet and is consistent with IgG reference spectra for β-sheet composition. The
addition of Seq576 resulted in similar spectra to IgG Pre-Melt, without the addition of
DNA. This result suggests pre-melt, the nucleic acids are not affecting the secondary
structure of the protein, Fig 5.10.
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Figure 5.10: CD spectra of 1.3μM IgG +/- 0.65μM molecules Seq576 pre-melt at room temperature. Prior
to heating, both samples have similar spectra, suggesting DNA is not affecting IgG secondary structure before
heating.

We used IgG without DNA as a control. We expected little to no signal, as most of
the protein precipitates out of solution. IgG Post-Melt, without the addition of nucleic
acids. displayed different spectra than that of IgG Pre-Melt, Fig 5.11. After heating,
precipitate was observed in the cuvette suggesting a portion of IgG was insoluble,
supporting data seen after thermal aggregation and spin down assays. IgG Post-Melt is a
representation of the very small amount of IgG that remained soluble throughout the
experiment, therefore, making interpretation of the remaining signal is difficult.
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Figure 5.11: CD spectra of 1.3μM IgG without nucleic acids control. Samples were observed during forward
and reverse melt. Pre-Melt spectra was measure at room temperature before heating. Post-Melt spectra was
measured at room temperature, and after heating to 85°C and cooling to room temperature. Most of the
protein precipitated out of solution, into the cuvette during heating. This is a representation of duplicate
experiments (Appendix, Fig. A.10).
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Figure 5.12: CD spectra of 1.3μM IgG +/- 0.65μM molecules Seq576. Samples were observed during
forward and reverse melt. Pre-Melt spectra was measure at room temperature before heating. Post-Melt
spectra was measured at room temperature, after heating to 85°C and cooling to room temperature. An
increase in minima was observed around 215nm for IgG+576 sample. Little change was seen after cooling
from 85ᵒC. This is a representation of duplicate experiments (Appendix, Fig. A.11).

Now that we observed spectra for the full melt of IgG without the presence of
nucleic acids, we then evaluated spectra when different types of DNA were added to the
protein. First, I observed the effects G-quad sequence Seq576 had on IgG secondary
structure composition, Fig 5.12. After adding Seq576, I evaluated the samples when they
were heated to 85°C, and subsequently cooled to room temperature. IgG+Seq576 PostMelt had significant spectral differences than IgG+Seqe576 Pre-Melt. The minimum
around 210nm was considerably larger after heating, with a small shift to smaller
wavelengths. In addition, a shift in the peak at 200nm to approximately 190nm was
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observed. In addition to testing G-quad forming sequence 576, I also tested bulk, htDNA
at a 5:1 ratio of DNA to protein, Fig 5.13. Comparable results to Seq576 were seen. This
reveals there is an increase in secondary structure when G-quadruplex DNA and bulk DNA
are present with IgG.
The large trough above 210 nm suggests an increase in β-sheet structure, Fig 5.12,
5.13. As discussed, increases in β-sheet structure could point to fibril formation or soluble
oligomeric intermediates. In this case, EM data displays the formation of soluble
oligomers. These results also indicate the structural changes are irreversible upon heating
and cooling of IgG + Seq576. Similar results were seen with bulk htDNA, Fig 5.13.
Overall, we can infer with the addition of G-quad forming sequence and bulk DNA, the
secondary structure of IgG increased after heating to 85°C and cooling to 25°C and is
maintained upon cooling.
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Figure 5.13: CD spectra of 1.3μM IgG +/- 6.5μM bp htDNA. Samples were observed during forward and
reverse melt. Pre-Melt spectra was measure at room temperature before heating. Post-Melt spectra was
measured at room temperature, after heating to 85°C and cooling to room temperature. Spectra at 85ᵒC and
Post-Melt are similar. A greater minimum is observed at 220 nm. Little change was seen after cooling from
85ᵒC. A peak around 190 nm is observed. This is a representation of duplicate experiments (Appendix, Fig.
A.12).

Increased secondary structure of proteins can be related to highly ordered
structures, such as amyloid fibrils. As mentioned, light chain IgG has the potential to be
amyloidogenic

33, 51, 76

. Previous studies performed by Micsonai suggest amyloid fibrils

related to different diseases can have broad spectral differences

98

. They tested amyloid

fibrils from AD patients, as well as Huntington’s disease, and dialysis-related amyloidosis.
Associated with kidney dialysis, microglobulin, β2m, is a light chain of MHC-I, which is
deposited as amyloid fibrils in the body

98

. Micsonai observed secondary structure of

mature and immature amyloid fibrils of β2m and used a variety of spectral analysis
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programs to estimate secondary structure 98. They found different CD spectra exist amongst
different diseases, in addition to mature and immature amyloid fibrils within a single
disease 98. Fibrils displayed β-sheet secondary structure, and immature fibrils had spectra
similar to our Post-melt spectra when nucleic acids were introduced 98. They attribute these
differences to the varying morphologies for each disease 98. Thus, we are unable to utilize
CD to formally conclude exact secondary structures; however, we can infer the spectral
changes seen are indicative of structural and conformational changes from the native
monomeric form of IgG when nucleic acids are present. This led to increased levels of
secondary structures. We therefore continued to employ additional methods to give insight
into IgG structural changes induced by DNA.

5.7 Tryptophan Fluorescence
The significant changes in secondary structure in the presence of nucleic acids led
to fluorescence experiments to further understand structural changes of IgG with and
without DNA. Intrinsic fluorescence shows the relationship between aromatic residues in
a protein, their solvent-exposure and their environment

18

. Aromatic residues are

commonly found buried within the native protein due to their hydrophobic nature, as well
as at domain-domain interfaces 100. When tertiary structure is disrupted, solvent-exposure
to these side chains can occur 100.
The most common amino acid observed via intrinsic fluorescence is tryptophan
(Trp), an aromatic amino acid whose fluorescence can be monitored using an excitation
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wavelength of 275-295nm, and fluorescence emission observed within 300nm to 350nm
96

. Generally, an emission peak near 320nm is observed prior to changes in the environment

of a protein. After conformational changes or a disruption in the native state of a protein, a
shift in the emission peak to a higher wavelength may be observed, also known as a red
shift 18 100. This is indicative of more solvent-exposed tryptophan residues 100 101. We can
utilize this technique due to the Trp content in monomeric IgG. Research determined highly
conserved Trp residues are located at the antigen binding site of IgG 102. Trp residues are
represented by yellow in Fig 5.14.

Figure 5.14: Crystal structure of mouse IgG antibody, where dark blue represents light chains and purple
represents heavy chains. Trp residues, represented by yellow, are located near the antigen binding site, and
throughout the molecule 102. This figure was produced using ChimeraX and sequence from Harris 8. It is
important to note, I used bovine IgG, not mouse, although Trp are highly conserved across families of IgG
molecules.
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For IgG with and without DNA, we expect to see changes in overall Trp
fluorescence spectra, as CD data and light scattering shows IgG structures evolved during
heating and cooling processes. We observed tryptophan fluorescence upon heating and
cooling to induce heat-stress of IgG. Using this technique, we can observe possible
conformational changes or general structural changes in the protein. Prior to heating, a peak
was observed near 330nm, with a low fluorescence intensity. This result suggests there are
few Trp residues exposed to solvent before unfolding 18,100.
For control samples without nucleic acids, at 85°C, a red shift in fluorescence was
detected, suggesting IgG is unfolding or undergoing conformational changes that result in
more Trp exposure to solvent, Fig 5.15. After heating and cooling to room temperature,
IgG Post-Melt, the peak shifted back to lower wavelengths, and a small increase in
fluorescence intensity. While a small increase was observed, it may be insignificant. It is
important to note, this data is difficult to interpret, as IgG is precipitating out of solution,
and falling in the cuvette.
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Figure 5.15: Trp Fluorescence of 1.3μM IgG without nucleic acids. Samples were observed before and after
a thermal aggregation assay. At 85°C and Post-Melt at 25°C, red shift (indicated by red line) in peak from
330nm to 345nm was observed. There was a negligible increase in fluorescence observed after the sample
was returned to room temperature, while maintaining the shift in wavelength, although to a lesser extent. This
is a representation of triplicate experiments. (Replicates found in Appendix, Fig. A.3).

Starting spectra for IgG with Seq576 is similar to that of IgG without nucleic acids,
Fig 5.16. After heating, a red shift is observed; however, after cooling we observe a large
increase in fluorescence intensity. Trp are sensitive to their environment and an increase in
fluorescence intensity could be a result of several different factors. For example, we
expected to see a quench in fluorescence intensity upon interactions with DNA, as previous
literature suggests DNA quenches Trp fluorescence upon binding 103, 101.
IgG also contains multiple Trp residues, therefore, it is difficult to determine what
specific interactions are occurring that may lead to enhanced fluorescence intensity.
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Additionally, fluorescence intensity can be changed by solvent polarity
amino acids

104

101

and adjacent

. More experiments would be necessary to determine what is causing the

increase in fluorescence.
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Figure 5.16: Trp Fluorescence of 1.3μM IgG + 0.65μM molecules Seq576. Samples were observed before
and after thermal aggregation assay. At 85°C and Post-Melt at 25°C, a red shift (indicated by red line) in
peak from 330nm to 345nm was observed. Additionally, an increase in fluorescence was observed after the
sample was returned to room temperature, while maintaining the peak intensity shift in wavelength, although
to a lesser extent. This is a representation of triplicate experiments performed. (Replicates found in Appendix,
Fig. A4).
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Figure 5.17: Trp Fluorescence of 1.3μM IgG + 1.3μM bp htDNA. Samples were observed before and after
thermal aggregation assay. At 85°C, a red shift (indicated by red line) in peak from 330nm to 345nm was
observed. An increase in fluorescence was observed after the sample was returned to room temperature, while
maintaining the peak intensity shift in wavelength, although to a lesser extent. This is a representation of
triplicate experiments performed. (Replicates found in Appendix, Fig. A.5).

Similarly, with the addition of bulk htDNA, a red shift in the spectra is observed,
and upon cooling, an increase in fluorescence intensity is seen, Fig 5.17. We cannot
conclude what is causing this increase in fluorescence, but it is clear the addition of DNA
during heating is leading to structural changes in the protein. We know structural changes
are occurring based on CD and Trp fluorescence data, and we can use Thioflavin T for
more structural data.
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5.8 Thioflavin T Assay
Thioflavin T, ThT, is a known fluorescent probe for amyloid fibrils. When excited
at 440-450 nm, an emission maximum of 482 nm is observed when interacting with fibrils
or oligomeric intermediates (Cayman Chemical).
ThT can bind to a variety of fibrils with different binding affinities. When ThT is
in solution, it can freely rotate about the C-C bond

78,105

. When bound to amyloid fibrils,

free rotation is no longer possible, resulting in fluorescence. Previous research determined
ThT interactions with oligomers is not as strong as with Aβ (1-40) or α-synuclein amyloid
fibrils

33

. Generally, some oligomeric species can be identified by an intermediate ThT

fluorescence emission, and other confirmatory techniques

33

. It has been proposed ThT

interactions with amyloid fibrils and ThT positive oligomers occur perpendicular to βstrands in the β-sheet, as opposed to parallel, or at the end of the β-sheet 105. It is important
to note, other research determined not all on-pathway oligomeric species are able to interact
with ThT 78. We can use ThT to measure the presence of oligomeric or fibrillar species in
solution when nucleic acids are present.
Thioflavin T is also a known fluorescent probe for RNA and DNA G-quadruplexes
106

. Generally, there are two areas of G-quads that are likely to interact with probes; groove

binding modes, or end-stacking 106. Research showed ThT likely interacts with G-quads by
interacting with the top of the G-tetrad 106. To evaluate the presence of nucleic acid-induced
IgG oligomeric intermediates, I used ThT fluorescence before and after heating. In addition
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to full melt of protein samples, I also performed the same experiments with nucleic acids
and buffer in the absence of IgG to determine if a strong interaction was occurring between
the nucleic acids, Seq576 or htDNA, and ThT. Negligible changes in ThT fluorescence
intensity upon heating and cooling was observed, Fig 5.18 Thus, I subtracted the nucleic
acids without IgG spectra from the IgG + Seq576 or htDNA data to evaluate the ThT
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Figure 5.18: Thioflavin T (ThT) fluorescence assay control of 0.65μM molecules Seq576 or 6.5 μM bp
htDNA. Samples were observed at room temperature before heating to 85°C and cooling to 25°C. ThT
fluorescence was observed prior to the sample being heated. After heating, negligible increase in fluorescence
was observed.

Results from ThT assays of IgG without nucleic acids control, Fig 5.19 displayed
little increase in fluorescence at 25°C after a full melt was performed. Based on thermal
aggregation and CD experiments, we know IgG without nucleic acids precipitates out of
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solution and is no longer soluble, therefore these results are difficult to interpret, as most
of protein was likely at the bottom of the cuvette. In addition, previous research has shown
ThT does not interact with amorphous aggregates or unfolded proteins 107. We expect after
thermal aggregation, full length IgG forms insoluble amorphous aggregates. I also used a
thermal aggregation and spin down assay to evaluate ThT fluorescence of IgG without
nucleic acids. No visible increase in fluorescence was observed in the soluble fraction
compared to IgG prior to aggregation and spin down assays; however, these results are
once again not interpretable as the protein is located in the insoluble fraction.
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Figure 5.19: Thioflavin T (ThT) fluorescence assay of 1.3μM IgG without nucleic acids control. Samples
were observed at room temperature before heating to 85°C and cooling to 25°C. Negligible amounts of ThT
fluorescence were observed prior to the sample being heated. After heating, a minimal amount of
fluorescence intensity increase was observed. This is a representation of triplicate experiments (Replicates
found in Appendix, Fig. A.6).
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Next, I measured ThT fluorescence of IgG samples with the addition of Seq576. In
the presence of Seq576, before heating, very little ThT fluorescence was observed. After
heating to 85ᵒC and cooling to 25°C, we see an increase in fluorescence intensity, Fig 5.20
(A). A very large increase in fluorescence intensity will occur when ThT is in the presence
of fibrils. Previous research using Aβ fibrils and oligomers has also shown intermediate
increases in intensity when prefibrillar oligomeric assemblies are present

108

. The sample

is ThT-positive, suggesting that the sample is forming states that are similar to amyloid
intermediates. To determine if this fluorescence was caused by the soluble fraction, I
performed a thermal aggregation assay with a spin down and tested ThT fluorescence
before and after, Fig 5.20 (B). An observable increase in ThT fluorescence was observed
after heating IgG + Seq576 when compared to no increase of IgG without the addition of
nucleic acids. This data supports the formation of oligomeric species in the presence of Gquad DNA and suggests that these oligomeric species have structural properties similar to
amyloid precursor intermediates.
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Figure 5.20: (A) Thioflavin T (ThT) fluorescence assay of 1.3μM IgG + 0.65μM molecules Seq576. Samples
were observed at room temperature pre and post thermal aggregation. After forward and reverse melting, an
increase in ThT fluorescence was observed. Seq576 + ThT without IgG samples were subtracted off shown
spectra to provide accurate measurements. (Replicates found in Appendix, Fig. A.7).
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Figure 5.20: (B) ThT fluorescence measure before thermal aggregation and spin down assay, and after,
using only the soluble fraction. Large increase in ThT fluorescence was observed for IgG+Seq576. ThT in
buffer was subtracted from IgG data, and ThT + Seq576 and buffer was subtracted from IgG + Seq576 data.
These represent triplicate experiments (Replicates found in Appendix, Fig. A.9).

Interestingly, the presence of htDNA causes a small increase in ThT fluorescence
after heating and cooling of IgG, Fig 5.21 (A). When compared to Seq576 spectra, this
increase is not nearly as high. This data is interesting, as it suggests oligomers induced by
htDNA are not the same as oligomers induced by G-quad Seq576, thus resulting in different
structures and varying ThT fluorescence. This could also be a result of the bulk DNA
sterically interfering with ThT binding to the protein; however, more experiments would
need to be performed to determine the reason behind the low fluorescence intensity. I also
measured ThT fluorescence before and after a thermal aggregation assay, using only the
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soluble fraction post thermal aggregation. Similar trends are seen, where ThT fluorescence
increases; however not nearly to the extent of when Seq576 is present with IgG, Fig 5.21
(B).
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Figure 5.21: (A) Thioflavin T (ThT) fluorescence assay of 1.3μM IgG + 6.5μM bp htDNA. Samples were
observed at room temperature pre and post thermal aggregation. After forward and reverse melting, an
increase in ThT fluorescence was observed. Seq576 + ThT samples were subtracted off shown spectra to
provide accurate measurements. (Replicates found in Appendix, Fig. A.8).
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Figure 5.21: (B) ThT fluorescence was measured before and after a thermal aggregation assay in the presence
of htDNA. Small amounts of fluorescence for IgG + htDNA occurred prior to heating. ThT in buffer was
subtracted from IgG data, and ThT + htDNA and buffer was subtracted from IgG + htDNA data. This is a
representation of triplicate experiments (Appendix, Fig. A.9).

Overall, after heating and cooling, we see an increase in ThT fluorescence when Gquad Seq576 was present in solution. The ThT fluorescence intensity level varies with
different types of DNA. G-quad forming sequence, Seq576, leads to a larger increase in
ThT fluorescence than bulk htDNA, which supports similar trends seen throughout our
previous research of G-quadruplexes being more efficient at promoting oligomerization 80.
This also indicates different types of DNA lead to oligomers that differ in overall structure
but contain similar secondary structure composition. Thermal aggregation assays
confirmed the soluble fraction leads to various increases in fluorescence ThT after heating.
With the addition of Seq576, the oligomers present in solution are ThT positive, meaning
they have some β-sheet content and may be similar to oligomeric intermediates.
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CHAPTER 6 DISCUSSION
Based on our results, we can conclude IgG forms soluble oligomers in the presence
of both G-quad Seq576 and bulk htDNA. The addition of DNA prevents the aggregation
of IgG. We observed increases in secondary structure via CD spectra when denatured in
the presence of DNA, which led us to inquire about IgG-DNA interactions. DNA promoted
structural changes of IgG, leading to soluble oligomer formation. IgG assemblies were
covalently linked. With the addition of Seq576, the soluble oligomers are ThT positive,
suggesting they are composed of some β-sheet secondary structure, indicating they may be
similar to prefibrillar intermediates. Additionally, bulk DNA led to small changes in ThT
fluorescence. In the absence of DNA, IgG forms insoluble aggregates, and are no longer
visible in the soluble fraction.
Using established thermal aggregation and spin down assays, we determined the
addition of nucleic acids maintained solubility of IgG by preventing aggregation. Gquadruplex, Seq576, prevented insolubility of IgG more efficiently than the bulk htDNA.
It has previously been determined increasing DNA concentration directly affects solubility
of a protein, where higher concentrations of DNA result in larger amounts of protein
solubility 30. The addition of DNA led to large protein assemblies which could not travel
in the gel. Based on the gel used, at 150 kDa, monomeric IgG would be able to travel in
the gel and be distinguishable from other bands. The largest marker we have is a 250 kDa
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band, therefore, oligomers would not travel far using this method, appearing in the same
band at the top of the gel. Additionally, these assemblies were covalently linked. We can
conclude without nucleic acids IgG formed insoluble aggregates. Based on the different
band patterns observed in the soluble fractions for both IgG and IgG with DNA, we can
infer the addition of DNA leads to different patterns of soluble protein assembly.
To confirm the results from the thermal aggregation and spin down assays, we used
light scattering to observe relative sizes of aggregates and soluble species being formed. A
significant increase in light scattering of IgG without DNA indicated the formation of
larger aggregates and/or larger amounts of aggregates. Fluctuations and a slight decrease
in light scattering during cooling could be due to IgG precipitating out of solution and
falling in the cuvette. This data further supports previous results from thermal aggregation
and spin down assays, where large, insoluble aggregates were observed.
Interestingly, when DNA was introduced, an increase in light scattering occurred,
confirming the formation of soluble protein assemblies. The lower intensity of light
scattering indicates species in solution are much smaller in the presence of DNA, and/or
there is a larger amount of soluble oligomeric species present. This information led us to
believe smaller oligomeric species are being formed when DNA is added to IgG samples,
at similar rates of formation as IgG insoluble aggregates. We can conclude based on spin
down results paired with light scattering data, that in the presence of DNA, soluble species
of IgG are being formed, that are smaller than insoluble IgG aggregates.
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Agitation stress is important to evaluate, as this is a common stress, and can occur
in the body, leading to unstable proteins and aggregates

93,94

. Our results indicated IgG

aggregated with shaking stress, and with the addition of DNA, aggregation was prevented.
Minimal amounts of aggregation were observed, without DNA, which led to difficulty in
assessing the effect nucleic acids had on agitated IgG. To induce more aggregation with
shaking, we can lower the pH of the solution. This has been found to lead to fragmentation
of IgG 109. Additionally, types of agitation-induced aggregates are dependent on pH, where
pH of the solution leads to different assemblies of soluble and insoluble assemblies 110. To
increase the amount of agitation-induced IgG aggregates, we can increase or decrease the
pH of the solution dramatically. Evaluating how nucleic acids affect agitation-induced IgG
aggregates would be more conclusive if more aggregation is seen initially. We hypothesize
that with increased amounts of agitation stress in addition to varying conditions, the
addition of DNA will continue to prevent aggregation of IgG.
We used CD to evaluate how DNA was changing the structure of IgG. IgG is
primarily β-sheet in secondary structure composition. The loss in spectra post-melt in the
absence of DNA tells us IgG precipitated out of solution into the cuvette. This is consistent
with thermal aggregation and spin down results, where IgG was found primarily in the
insoluble fraction. With the addition of G-quad Seq576, we can conclude that secondary
structure increased based on the more pronounced peaks, maximum and minimum, of the
CD spectra. With the addition of bulk htDNA, CD results were similar to that of IgG +
Seq576. It is clear the addition of G-quad forming sequence or bulk DNA induced
structural changes in IgG with similar efficiencies. Interestingly, previous observations of
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proteins heated with nucleic acids resulted in less secondary structure

30,80

; however, we

saw an increase with IgG and DNA. This increase in secondary structure can be a result of
higher ordered protein intermediates. We know light chain IgG can form oligomeric
intermediates that lead to the formation of amyloid fibrils, which are highly ordered
structures.
Unfortunately, CD spectra are not consistent across different amyloid-forming
proteins and their intermediates. Generally, amyloid fibrils are composed primarily of βsheets, thus resulting in spectra consistent with β-sheet reference spectra; however, this is
not always the case. For example, CD spectra for mature β-2 microglobulin amyloid fibrils
are indicative of β-sheet composition, versus immature β-2 microglobulin amyloid fibrils,
where their CD spectra is similar to what we are observing after heating and cooling 98. To
determine if IgG structures being formed with the addition of DNA are prefibrillar, we
need to perform similar experiments on the variable domain and light chain of IgG instead
of full-length, as full-length IgG is not found in AL amyloids. We know nucleic acids can
change the structure of full-length IgG, showing the potential for light chain IgG
interactions with DNA.
To further evaluate IgG interactions with DNA and to observe the environment
around the protein, we used tryptophan fluorescence spectroscopy, as IgG contains
multiple Trp residues, near the antigen binding site of the Fab region and throughout the
molecule 8, 103. Without nucleic acids, after heating IgG displayed a spectral red shift, which
is indicative of more solvent-exposed Trp residues. This indicates IgG is denatured as
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temperature increases. Upon cooling, the spectra slightly shifted to a lower wavelength,
suggesting Trp was not as exposed after cooling, indicative of aggregate formation, which
is consistent with spin down and light scattering data. This data does not rule out other
misfolded states that are not aggregate or oligomeric, but as displayed in SDS-PAGE, no
misfolded monomeric states were observed. Based on CD data, it is clear if refolding
occurred after cooling, it is not natively folded IgG.
With the addition of G-quad and bulk DNA, in both cases, we see a similar red shift
upon heating; however, after cooling an increase in Trp fluorescence is observed, in
addition to a slight blue shift to a lower wavelength. This data contradicts what is normally
observed when DNA binds to proteins. Generally, upon binding to DNA or
oligonucleotides, Trp fluorescence is quenched, not enhanced 102,103. Quenching can occur
when nucleotides are stacked with the fluorophore, in this case, Trp. Interestingly, guanine
has been found to be the most efficient at quenching fluorescence

102

. We did not expect

these results from this experiment; however, Trp fluorescence can be influenced by many
different factors. Trp fluorescence can be quenched by different ligands, in addition to
proximity to certain amino acids

104

. It is known that Trp is sensitive to its local

environment and IgG contains multiple Trp, which can all be influenced by different
environments during experiments, making interpretations difficult. To better evaluate
conformational changes, and local environments around Trp, we would need to only
observe a single Trp at a time. Additionally, light scattering can directly affect observed
Trp emission intensity and shifts

111

. Overall, these results tell us as IgG is heated,
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unfolding is occurring in all three cases; however, more experiments need to be performed
to further evaluate the fluorescence increase in the presence of DNA upon cooling.
Electron microscopy images further support data from multiple different
experiments. EM is unique in that it can provide images displaying relative sizes and
structures of oligomers or aggregates from being formed by thermal aggregation. In
addition, it can be used to confirm previous results that suggest oligomer formation is
occurring in the presence of DNA. EM images of IgG in the presence of both Seq576 and
bulk htDNA display the formation of oligomers in the soluble fraction. There were slight
differences in shapes of oligomers with the addition of Seq576 versus htDNA. We can
conclude the addition of DNA is promoting soluble oligomerization of IgG. We were able
to gain more information about DNA-induced IgG oligomers using thioflavin T.
It is important to note we expected to see significant interactions between ThT and
Seq576, as ThT is known to bind with high specificity to G-quadruplex structures 106,112.
Our observed interactions with ThT and Seq576 were not as expected, where interactions
were minor to moderate and did not interfere with our ability to observe changes in IgG in
the presence of nucleic acids. We also saw minor interactions between ThT and htDNA;
however, ThT is not known to interact well with other DNA structures 112.
The lack of increased ThT fluorescence in the absence of DNA is not surprising;
similar to other experiments, IgG precipitated out of solution and likely was not being
detected in this experiment. This was confirmed after a ThT assay was performed on the
soluble fraction, where we still saw no increase in ThT fluorescence.
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In the presence of both G-quad Seq576 and bulk DNA, an increase in ThT
fluorescence was observed in the soluble fraction; however, the fluorescence increase was
not extreme after a full-melt in the presence of htDNA. The increase in ThT fluorescence
of the soluble fraction is consistent with spin down results. While ThT bound to fibrils
results in significant increases in ThT fluorescence, ThT-positive oligomers previously
observed interact with ThT to a lesser extent

113

. This can be caused by ThT interactions

with hydrophobic regions of the oligomer 108, or β-sheet rich portions. Other studies have
shown some on-pathway oligomers are not detected by ThT 78. It is possible there is a lack
of β-sheet rich portions in ThT-negative oligomers. We know in the presence of DNA, IgG
does not form insoluble aggregates, therefore, the increase in ThT fluorescence may be
attributed to the presence of oligomeric species and potential exposure of hydrophobic
patches of IgG oligomers. Additionally, this could indicate the presence of β-sheets in these
IgG oligomers, as ThT is known to interact with β-strands 105. We can conclude the increase
in fluorescence observed is due to interactions with soluble oligomers, as only minor
interactions between ThT and Seq576 alone were observed. More experiments need to be
performed to determine why bulk htDNA did not lead to a comparable increase in ThT
fluorescence. Additionally, it is possible the interactions between DNA and protein are
leading to either exposed hydrophobic patches or, exposed nucleobases. More research
would need to be performed to determine the interactions that are occurring between the
DNA and protein. ThT fluorescence data shows the potential for nucleic acid-mediated
oligomeric intermediate and amyloid formation with IgG light chains.
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Our EM data paired with ThT assays for IgG in the presence of DNA showed the
formation of oligomeric species, which are ThT positive, suggesting these oligomers had
some degree of β-sheet secondary structure and are similar to amyloid intermediates. ThT
has higher specificity to amyloid fibrils and interacts with β-sheets. With the addition of
both G-quad Seq576 and bulk htDNA, IgG forms soluble oligomers and is no longer
aggregating. Based on CD and fluorescence data, we can conclude structural changes are
occurring in the presence of DNA and ThT positive oligomeric species are being formed
with the addition of G-quad Seq576.

Figure 6.1: Proposed model for Seq576 interactions with full-length IgG. After heat stress, we propose
electrostatic interactions occur between positively charged residues of IgG and the negatively charged
backbone of Seq576. Additionally, aromatic residues may interact with hydrophobic nucleobases of the Gquad sequence. Solvent exposed Trp residues are present, suggesting conformational changes that occur lead
to rearrangement of Trp.

This data is valuable as it displays a clear interaction between full-length IgG and
DNA, including structural changes and induced oligomerization, Fig 6.1. We propose
interactions that occur between IgG and Seq576 can be electrostatic, and interactions
between aromatic residues and nucleobases are possible. Conformational changes lead to
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exposed Trp residues, and new shapes. The red shift in Trp fluorescence after heating and
cooling suggests Trp are solvent-exposed, leading us to believe DNA is not directly
interacting with all Trp residues. To our knowledge, there has been no previous research
published on the potential interactions between amyloidogenic light chain IgG and nucleic
acids. This is an important avenue of research as IgG light chains are known to form
amyloid fibrils, leading to light chain amyloidosis. Nucleic acids are known cofactors in
other amyloidogenic diseases, including AD and PrP 52,81,83,88,92.
Understanding the relationship between DNA and light chain IgG can lead to a
further understanding of light chain amyloidosis, in addition to potential therapeutic
solutions, as AL amyloidosis is currently not curable. Co-factors are negatively charged
molecules, which can promote fibril formation, as discussed previously. Previous data
suggests GAGs interact with light chain IgG via electrostatic interactions, where the
negatively charged sections of the co-factor molecules interact with positively charged
areas on the light chain, in addition to the variable domain 26. Nucleic acids interacted with
different tau constructs to assist fibril formation

52

. While each protein has its own

pathology, similar events can lead to amyloid fibril formation. We know light chain IgG
can interact with different cofactors electrostatically, thus we can predict nucleic acids may
interact with positively charged portions of light chain IgG, potentially promoting
oligomerization and/or fibril formation. The next phases of the research are to perform
similar assays and induced amyloid formation of light chain IgG in the presence of nucleic
acids. As a lab we intend to start research with germline light chain IgG, and amyloidogenic
light chain IgG. We will also stain kidney tissues from a patient with AL amyloidosis for
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nucleic acids to determine if they are embedded in tissues. We have shown nucleic acids
can interact with full length IgG therefore it is necessary to determine if this interaction is
true for light chain IgG.
If the addition of G-quad DNA can induce the formation of ThT positive oligomers
of full-length IgG, how would DNA influence light chain IgG? Given our previous
knowledge of other amyloidogenic proteins and nucleic acids as cofactors, it is important
to determine the potential effect DNA would have on light chain IgG, as this portion of the
protein leads to systemic AL amyloidosis. The interaction between DNA and light chain
has not previously been studied and could be a missing step in the pathway, leading to more
understanding and potential treatment targets.
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CHAPTER 7 MATERIALS AND METHODS
Immunoglobulin G and Seq576
We used Immunoglobulin G from bovine serum from (Sigma-AldrichI5506). Prior
to reconstitution, lyophilized IgG was stored in 4°C. Lyophilized IgG was reconstituted
using 10 mM potassium phosphate buffer (pH 7.0), in a range of concentrations from 1
mg/mL to 5 mg/ml. IgG was aliquoted out and stored in -20°C. Concentrations were
checked using NanoDrop, absorbance at 280 nm.
Seq576 was previously developed in the Horowitz Lab after testing a variety of
ssDNA sequences, including G-quad forming sequences 80. Seq576 nucleobase sequence:
5’ TGT CGG GCG GGG AGG GGG GG 3’. Seq576 was custom ordered from IDT and
reconstituted using a 10mM potassium phosphate buffer. Concentrations checked using
NanoDrop, absorbance at 260 nm and molar extinction coefficient, 196700 M-1 cm-1.
Aggregation Assays
To evaluation aggregation of IgG, aggregation assays consist of three parts. First,
denaturation of the protein, using thermal or agitation stress. To evaluate the soluble and
insoluble fractions of samples, spin down assays were used followed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, SDS-PAGE.

72

Thermal Aggregation
Thermal aggregation assays were modified from previously developed protocols 30.
Samples were heated 75ᵒC for 15 minutes. After these studies, G-quadruplex structures
were found to be more stabilized in the potassium phosphate buffer, therefore, the
potassium phosphate buffer was used for my experiments. I also used pH 7.0 as bovine
IgG from serum range in pI values, from a minimum of 5.5 to maximum of 8.5

118

. My

concentration used was 0.2mg/mL, equivalent to 1.3μM (Vermeer). After optimization, the
final volume for samples was 50μL. 1.3μM IgG was mixed with or without 0.65μM
molecules Seq576 or 6.5μM bp herring genomic DNA (htDNA) and brought to final
volume with 10mM potassium phosphate buffer (pH 7.0). The samples were heated on
Eppendorf ThermoMixer C for 15 min, at 75°C with shaking of 400rpm. Temperature was
chosen after full-melt CD spectra was performed to determine melting temperature of
bovine IgG.
Agitation
Agitation conditions were adapted as previously described

44

. We induced

aggregation via agitation by shaking samples using Eppendorf ThermoMixer F1.5 for
72hrs. Shaking stress of 1200 rpm, at 20°C 44. Multiple factors affect agitation of proteins,
including low and high pH 110. To keep neutral pH conditions, we modified the protocol,
and used a 10 mM potassium phosphate buffer (pH 7.0). Following the protocol of Serno,
after shaking samples for 72hrs at 20°C, no aggregation was observed. The temperature
was raised; however, not above the melting temperature of IgG. Research by Chen et al.
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on thermal stability of bovine milk IgG suggested there was no decline of IgG activity at
62.5°C 114. Therefore, samples were shaken at 60°C. Final concentrations used: 3.3μM IgG
with/without the addition of 3.3μM molecules Seq576 or 16.5μM bp htDNA. 10mM
potassium phosphate buffer was used for all samples. To evaluate samples, agitation assay
was paired with spin down assay.
Spin Down Assay
Spin down protocol was modified from previous methods 30,79. Samples were spun
down in Fisher Scientific accuSpin Micro 17R at 4°C, 16.1k x g after thermal aggregation
assays. The protocol was modified by changing the time to 15 minutes

30

. For the total

fraction, 10μL was taken out prior to spin down. 10 μL of the supernatant was taken out
for soluble fractions. Additional supernatant volume was removed from the
microcentrifuge tube. Pellets were reconstituted with 1x TG-SDS buffer to original
volume. 10μL of sample was removed to represent pellet fraction 30,79.
SDS-PAGE
10μL of samples [total, supernatant, pellet] were prepared with 8μL of nonreducing bioWORLD SDS-Sample Buffer 4x. Additionally, 5μL of 20mM dithiothreitol,
DTT, reducing agent was added to samples for reducing conditions, unless non-reducing
conditions were desired. 1x TG-SDS buffer was used to reach a final volume of 40μL. We
used BIO RAD Mini-PROTEAN TGX stain-free gels, 12%, 15-well, 15μL with BIO RAD
Precision Protein Ladder. Gels were performed with constant voltage, 200V. For gel
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staining, we used Coomassie Blue stain, and Fairbanks A, B, C and D, components for
each listed below. Fairbanks A was added to the container with gel, microwaved for 1
minute and swirled for 10 minutes. Fairbanks A was removed, and Fairbanks B was added
and microwaved for 1 minute. Once the sample cooled, B Fairbanks B was removed, and
the same process was repeated for Fairbanks C. After, Fairbanks D was added, and gel was
swirled for 10 minutes before using BIO-RAD Image Lab Touch Software.
Fairbanks A: 250mL 2-propanol, 100mL glacial acetic acid, 0.5g Coomassie R-250,
650mL ddH20
Fairbanks B: 100mL 2-propanol, 100mL glacial acetic acid, 0.05g Coomassie R-250,
800mL ddH20
Fairbanks C: 100mL glacial acetic acid, 0.02g Coomassie R-250, 900mL ddH20
Fairbanks D: 100mL glacial acetic acid, 900mL ddH20
Light Scattering Assay
All

samples were measured using

Varian Cary Eclipse fluorescence

spectrophotometer, with a Quantum Northwest TC 125 temperature controller. Final
sample volumes were 200μL with final concentrations of 1.3μM IgG with/without the
addition of 0.65μM molecules Seq576 or 6.5μM bp htDNA. Samples were excited at 340
nm and emission was observed at 340 nm. At time=0, the temperature was at 25°C prior to
heating. Light scattering intensity was recorded data for a total of 84 minutes while heating
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IgG to 85°C, which is at time=42 minutes, and continued recorded while cooling until 25°C.
Buffer with and without DNA was also recorded and additionally plotted.
Tryptophan Fluorescence
All

samples were measured using

Varian Cary Eclipse fluorescence

spectrophotometer, with a Quantum Northwest TC 125 temperature controller. Final
samples volumes were 200μL with final concentrations of 1.3μM IgG with/without the
addition of 0.65μM molecules Seq576 or 6.5μM bp htDNA. Initial measurements were
taken at 25°C, and at intervals of 2.5°C until heated to 85°C. The samples were then cooled,
with measurements same parameters until cooled to 25°C. An excitation wavelength of 275
nm was used, measuring emission from 300 nm to 420 nm. 10mM potassium phosphate
buffer and nucleic acid spectra (when present) were subtracted off data accordingly.
Circular Dichroism
For CD measurements, we used Jasco J-1100 CD spectrometer. 1.3μM IgG was
prepared with 0.65μM molecules Seq576 or 6.5 μM bp htDNA and 10mM potassium
phosphate buffer (pH 7.0). For full melt, samples had final volume of 400μL.
Measurements were taken every 10°C and temperature was increased from 25°C to 85°C
with ramp rate of 1°C/min. Samples were cooled back to 25°C with the same conditions.
At 25°C for forward and reverse melt, in addition to 85°C samples were measured with 3
accumulations. For IgG without nucleic acids, buffer spectra was subtracted from data. For
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IgG with nucleic acids, Seq576 + buffer, or htDNA + buffer spectra were subtracted from
the data.
ThT Assay
Thioflavin T was purchased from Cayman Chemicals (32553). ThT concentrations
were determined using NanoDrop UV-Vis, measuring absorbance at 412 nm and molar
extinction coefficient of 31600 M-1 cm-1 115. ThT fluorescence was measured using Varian
Cary Eclipse fluorescence spectrophotometer with a Quantum Northwest TC 125
temperature controller. 1.3μM IgG with/without 0.65μM molecules Seq576 or 6.5μM bp
htDNA and 15μM ThT were brought to final volume of 200μL using 10 mM potassium
phosphate buffer (pH 7.0). Measurements were recorded every 2.5°C starting at 25°C to
85°C and cooled to 25°C. Excitation wavelength of 440 nm was used, in addition to
emission measurements from 460 nm to 520 nm

116

. 10 mM potassium phosphate buffer

and ThT with or without nucleic acids were subtracted from data.
TEM
TEM methods were developed from previous studies 30. I used thermal aggregation
assays with 100 μL samples (described in Thermal Aggregation). Samples contained
3.9μM IgG with/without the addition of 1.95μM molecules Seq576 or 90μM bp htDNA.
Immediately after thermal aggregation, a spin-down assay was performed (described in
Spin Down Assay). Approximately 99μL of the soluble fraction was removed for TEM
analysis. 5μL samples were undiluted before placement on the grid. A negative charge was
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applied to grids. Each sample was applied to a charged grid. The grids used were stained
with 2% uranyl acetate solution

30

.We modified this protocol by changing the applied

charge to negative, as pI for the two allotypes of IgG from bovine serum vary, from a
minimum of 5.5 to maximum of 8.5

117

. Previous protocols for TEM of IgG used uranyl

acetate 78.
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APPENDIX

Thermal Aggregation

Figure A.1A

Figure A.1B

Replicates of thermal aggregation assay and spin down of Figure 5.1

Replicates of thermal aggregation assay and spin down of Figure 5.2
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Agitation Assay

Figure A.2

Replicates of agitation assay and spin down of Figure 5.3
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Figure A.3 (A) Replicate of Trp fluorescence, IgG without nucleic acids of Figure 5.15
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Figure A.4 (A) Replicate of Trp fluorescence, IgG + Seq576 of Figure 5.16
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Figure A.5 (A) Replicate of Trp fluorescence, IgG + htDNA of Figure 5.17
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Figure A.6 (A) Replicates of ThT assay, IgG without nucleic acids of Figure 5.19
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Replicates of ThT assay, IgG without nucleic acids of Figure 5.19
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Figure A.7 (A) Replicates of ThT assay, IgG + Seq576 of Figure 5.20 A
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Figure A.8 (A) Replicate of ThT assay of IgG + htDNA of Figure 5.21 A
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Replicate of ThT assay of IgG + htDNA of Figure 5.21 A
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Replicate of ThT assay using plate reader of IgG + Seq576 or htDNA of Figure 5.20 and
5.21 B
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Duplicate of light scattering assay for IgG without nucleic acids, Figure 5.6 A
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Figure A.14

Duplicate of light scattering assay for IgG without nucleic acids, Figure 5.6 B
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